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THE PKZ1 RECOMBINATION MUTATION ASSAY: A SENSITIVE ASSAY FOR
LOW DOSE STUDIES
P. J. Sykes, A. A. Morley, A. M. Hooker  Department of Haematology and
Genetic Pathology, Flinders University and Flinders Medical Centre, Bedford Park,
SA, Australia
 The majority of mutation studies are performed at high doses of DNA damaging
agents due to the insensitivity of most mutation assays. Extrapolation using a linear no-
threshold (LNT) dose response model is then used to estimate the extent of possible DNA
damage at lower doses. There is increasing evidence to suggest that the LNT model may
not be correct at low doses of at least some DNA damaging agents. The pKZ1 in vivo and
in vitro recombination assays have proven to be very sensitive for detection of changes in
chromosomal inversion in lymphoid tissue in response to low doses of DNA damaging
agents. Non-linear dose response curves for chromosomal inversion as an end-point have
been identified at low doses of DNA damaging agents using this assay. Here, we review the
inversion results obtained to date with the pKZ1 assays and discuss their suitability for low
dose studies. 
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INTRODUCTION
Nearly all laboratory studies of mutagens and carcinogens involve
high levels of exposure, whereas the importance of mutagens and car-
cinogens for human populations involves the exposure of relatively large
numbers of individuals to relatively low doses of the specific agent.
However, the majority of mutation assays are only capable of detecting
mutations at high doses of agents. Therefore, at present, safe levels of
environmental and occupational agents are determined largely by extrap-
olation of data obtained using high doses of agents rather than from true
measurements. Extrapolation generally uses the linear no-threshold
(LNT) model, which is based on the conventional paradigm that an agent
which produces a harmful effect at a high dose will produce a similarly
harmful effect at low doses. There is a need for assays that enable study
of doses of agents which are relevant to environmental exposure. If some
or all mutagens are anti-mutagenic at low doses then current concepts of
low dose population exposure may need substantial revision. Hazard
assessment for toxicological agents would need to be changed to accom-
modate this new paradigm. Furthermore, understanding the mechanism
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of such an anti-mutagenic effect could ultimately lead to new insights into
situations such as cancer and aging in which mutagenesis is important.
There are several lines of evidence that suggest that the conventional
paradigm might not always be correct. The term hormesis was invoked to
describe the phenomenon whereby small doses of irradiation might actu-
ally be advantageous in terms of increasing life-span (reviewed in Upton,
2001). The proposed mechanism behind this phenomenon has involved
an adaptive response whereby low doses of radiation could, for example,
stimulate the expression of repair enzymes, which repair not only the X-
radiation induced mutations, but also other mutations in the cell, thus
reducing the overall mutation frequency (a J-curve response). This type
of response could equally be hypothesised for any low level of genotoxic
agent in the environment. All organisms including humans have evolved
in the presence of low doses of genotoxic agents and have evolved mech-
anisms to cope with them. These mechanisms are likely to have com-
monalities at the level of maintenance of DNA integrity. Calabrese and
Baldwin (2001a) have defined experimental criteria necessary for study-
ing low dose responses. These criteria include the need to use assay sys-
tems which are very sensitive in vitro and in vivo with the same mutation
end-point over a wide dose range, and have an endogenous mutation fre-
quency which is relatively high in order to see reductions in frequency
below endogenous frequency. Most mutation assays and studies of low
dose effects have been unable to fulfil many, let alone all of these criteria.
Our laboratory has recently made several observations that suggest
that the conventional paradigm of LNT-dose response is incorrect for at
least some agents. Somatic intrachromosomal recombination, which
leads to chromosomal deletions and inversions, is an important muta-
tional mechanism in cancer. We have been studying DNA damaging
agents using the pKZ1 transgenic mouse as a mutation assay with
somatic intrachromosomal inversion as the end-point. Here we review the
results obtained at low doses of DNA damaging agents using the pKZ1
inversion assays and discuss their suitability for low dose mutation studies. 
THE PKZ1 TRANSGENIC MOUSE
The pKZ1 mouse was originally developed by Matsuoka et al. (1991)
to study somatic DNA recombination in the brain. The pKZ1 transgenic
founder was an F2 C57BL/6J X DBA2 mouse and the subsequent trans-
genic progeny were backcrossed to C57BL/6J mice. The pKZ1 transgene
is described in detail in Matsuoka et al. (1991). Briefly, the transgene is
comprised of an E. coli β-galactosidase gene (LacZ) which is in inverse ori-
entation with respect to a chicken β-actin promoter. The transgene is
flanked by the mouse immunoglobulin gene recombination signal
sequences J
κ5 and Vκ21C. The pKZ1 mice are outbred to C57BL/6J mice
resulting in 50:50 transgenic:non-transgenic progeny (n = 1164, p = 0.42,
P. J. Sykes, A. A. Morley, and A. M. Hooker
92
2
Dose-Response: An International Journal, Vol. 4 [2014], Iss. 2, Art. 4
https://scholarworks.umass.edu/dose_response/vol4/iss2/4
Chi Square). Transgenic animals are identified using DNA from mouse
tail clippings and an E. coli lacZ-specific polymerase chain reaction (PCR)
which has previously been described in detail (Bej et al. 1990; Sykes et al.
1998). When an inversion occurs in the transgene, facilitated by the
recombination signal sequences, the lacZ gene is brought into the correct
juxtaposition with respect to the β-actin promoter and the lacZ gene can
now be expressed (Fig 1). 
ANALYSIS OF INVERSIONS IN PKZ1 TISSUES
The E. coli β-galactosidase protein (β-gal) can be detected in frozen
mouse tissue sections using the chromogenic substrate X-gal (5-bromo-4-
chloro-3-indolyl-β-galactopyranoside) which results in a blue stain. The
blue staining cells can be counted under the light microscope and an
inversion frequency is obtained by calculating the number of blue stain-
ing cells divided by the total number of cells counted. 
The method for tissue preparation, X-gal staining and calculation of
inversion frequency are described in detail in Sykes et al. (1998) and
colour photographs of positive staining cells have been published previ-
ously (Sykes et al. 1998; Hooker et al. 2004a). Scoring of blue staining cells
is time consuming and requires considerable expertise, suggesting that
analysis might be subject to operator bias. The mean endogenous inver-
sion frequency observed in spleen can differ between operators but the
overall spread of data observed within operators is similar (data are pre-
sented for three operators in Fig 2). For the pooled data in Fig 2, the 95%
confidence interval for the mean inversion frequenciy in pKZ1 animals is
Sensitive mutation assay for low dose studies
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FIGURE 1: The pKZ1 transgenic mouse construct. LacZ, E. coli β-galactosidase gene; EP, chicken β-
actin enhancer/promoter complex; V
κ21C and Jκ5, mouse immunoglobulin recombination signal
sequences (adapted from Hooker et al. 2004b).
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1.45 to 1.75 x 10–4 (n = 264), and approximately 5% of animals exhibit
unusually high inversion frequencies. These high inversion frequencies
may be the result of localised clonal expansion of a cell which has under-
gone an inversion within the haemopoietic system .
Intra-animal variation was determined by analysing the inversion fre-
quencies of fifteen untreated pKZ1 animals, scored on at least two occa-
sions on new frozen sections, and separated by a time period ranging
from 3 weeks to 8 months. There was no statistical difference in the inver-
sion frequency between replicate counting of inversions within an animal
(p= 0.24, Exact Friedman Test) indicating that differences in time of
freezing, preparation and sectioning did not significantly affect the
observed inversion frequency.
The expression of the E. coli β-gal is differentiated from the endoge-
nous mammalian β-gal by ensuring that staining is performed at pH 7.4.
(MacGregor et al. 1987). Non-transgenic and treated non-transgenic ani-
mals are always included in the experimental design to account for any
non-specific staining due to mammalian β-galactosidase. Non-specific
staining in untreated non-transgenic animals is rare. The mean frequen-
cy of non-specific staining observed to date in spleen of 58 untreated non-
P. J. Sykes, A. A. Morley, and A. M. Hooker
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FIGURE 2: Boxplot comparison of operators (BM, TD & TH) showing the median ± interquartile
range for inversion frequencies in spleen of pKZ1 untreated animals. The black bar indicates the medi-
an inversion frequency and the box represents the interquartile range (middle 50% of values). The
error bar indicates the next quartile range (25%) of inversion frequencies. The open circles and aster-
isks indicate outliers and extreme outliers respectively. For BM (n = 40), TD (n = 30), TH (n = 194).
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transgenic animals is 1.22 ± 0.73 × 10–6. Non-specific staining is increased
after administration of very high doses of DNA damaging agents rang-
ing from 8.9 ± 4.6 × 10–5 after whole body exposure to 2 Gy X-radiation
to 1.3 ± 0.3 × 10–4 after IP injection of 50 mg/kg etoposide. Non-specific
staining observed in treated non-transgenic animals is always subtracted
from the staining observed in treated pKZ1 animals.
ENDOGENOUS INVERSION FREQUENCY IN PKZ1 TISSUES
Spleen was chosen as the first tissue for mutational analysis as spleen is
a relatively homogeneous tissue for ease of scoring of blue staining cells in
a total number of cells in any one microscope field. The mean endogenous
frequency (±SE) observed in pKZ1 spleen is 1.61 ± 0.08 × 10–4 (n = 264) and
the frequencies ranged from 0 – 8.57 × 10–4. The endogenous inversion fre-
quency in spleen in pKZ1 animals follows a log normal distribution. 
The endogenous inversion frequency in spleen in pKZ1 mice increas-
es two-fold with age from 1.54 ± 0.24 × 10–4 in 4-month old mice to 3.12 ±
0.67 × 10–4 in 22 month old mice (Sykes et al. 1998). There is no difference
in endogenous inversion frequency in spleen between 4-month old pKZ1
males (1.5 ± 0.1 × 10–4, n = 64) and females (1.4 ± 0.09 × 10–4, n = 53) (p =
0.51, Mann-Whitney U test). After correction for transgene copy number
(pKZ1 mice have 15 copies, Matsuoka et al. 1991), the endogenous inver-
sion frequency for 4-month old mice equates to 1 × 10–5/copy. This is 50-
fold higher that that observed in spleen for point mutations in 8-10 week-
old Muta™Mouse (Myhr, 1991) and 25-fold higher than 6-8 week
BigBlue® mice (Köhler et al. 1991) when corrected for copy number.
Comparison with in vivo results in pKZ1 transgenic spleen indicate that
the endogenous inversion frequency observed in this study was approxi-
mately 15-fold less than that observed by Dempsey et al. (1993) for spon-
taneous H-2 mutants via mitotic recombination and 7 fold higher than
that observed for HPRT mutations (Dempsey and Morley, 1986; Jones et
al. 1985).
Inversions in the pKZ1 transgene have been identified in other tissues
in pKZ1 mice. Matsuoka et al. (1991) demonstrated that inversions
occurred in the brain, spleen, marrow and to a lesser extent in thymus by
histochemistry. Inversions have also been identified in pKZ1 prostate lumi-
nal epithelial or basal cells (Hooker et al. 2004a). Studies on different
stages of foetal and neonatal development in the brain of pKZ1 mice
revealed that E. coli β-gal activity was widespread in the central nervous sys-
tem and was not random, suggesting that inversion occurs early in devel-
opment of the pKZ1 mouse brain. Matsuoka et al. (1991) also designed
polymerase chain reaction (PCR) primers for detection of inversion events
in the pKZ1 transgene at the DNA level, and sequenced PCR products
from spleen and brain to identify the molecular DNA breakpoints at the
inversions. They demonstrated that the inversion breakpoints in spleen
Sensitive mutation assay for low dose studies
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involved the heptamer-nonamer sequences found in immunoglobulin
gene rearrangements (Sakano et al. 1979) suggesting that the
RAG1/RAG2 complex may be involved in resolution of the inversion
event. Studies in other tissues by Southern analysis of inversion PCR prod-
ucts revealed inversion events at the molecular level in spleen, thymus and
liver, however no inversion events were detected in tail or kidney tissue
(Matsuoka et al. 1991). We utilised the same PCR primers in a semi-quan-
titative limiting dilution PCR analysis on pKZ1 spleen DNA and demon-
strated that the frequency of inversion events closely approximated that
observed by histochemistry of frozen spleen sections (Sykes et al. 1998). 
THE PKZ1 ASSAY AS AN IN VIVO MUTATION ASSAY
Three- to four-month old animals were chosen for all subsequent
studies as this age represented young but mature animals. A time course
study was performed for exposure to 1 mg/kg cyclophosphamide to
determine the time at which maximal induction of inversions was
observed. Spleen was analysed from groups of animals either at 1, 3, 7 or
14 days after cyclophosphamide treatment. The results are presented in
Fig 3. A statistically significant induction in inversions was observed at all
P. J. Sykes, A. A. Morley, and A. M. Hooker
96
FIGURE 3: Mean inversion frequency (± SE) in spleen of 4-month old pKZ1 mice observed at 1, 3,
7 or 14 days after a single IP injection of 1 mg/kg cyclophosphamide. n = 5 for all treatment groups
in each experiment. (*) Significant increase in inversion events between (untreated pKZ1 – untreat-
ed non-transgenic) and (treated pKZ1 – treated non-transgenic) (p <0.05, two-tailed unpaired Mann-
Whitney U-test).
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time-points of analysis. The fold induction rose from 1.6-fold (p = 0.048)
at day 1 to 3-fold (p = 0.001) at day 3 and then decreased to 2.1- (p =
0.016) and 2-fold (p = 0.028) at days 7 and 14 respectively (two-tailed
Mann-Whitney U test). Day 3 post-treatment was chosen for all subse-
quent experiments and it was expected that most DNA repair would have
been completed by this time. Time-course experiments in vivo have not
been performed for other DNA damaging agents. Initial experiments
performed to determine if a variety of DNA damaging agents would
induce inversions involved intraperitoneal injection of single high doses
of DNA damaging agents, or whole body X-radiation, with subsequent
analysis of spleen tissue for chromosomal inversions in the pKZ1 trans-
gene. An induction in inversions was observed 3 days after treatment with
a range of different DNA damaging agents; cyclophosphamide, mito-
mycin C, etoposide, X-radiation and methylene chloride (Sykes et al.
1998; 1999). All of these agents are mutagens in a number of mutation
assays as well as known carcinogens. Cyclophosphamide is an alkylating
agent which can result in guanine adducts in the DNA, mitomycin C is an
alkalating cross-linking agent, etoposide is a topoisomerase II inhibitor,
and X-radiation causes results in DNA strand breaks and free radicals
which can damage DNA. Methylene chloride was chosen for study
because it is known to be carcinogenic in animals and causes intrachro-
mosomal recombination but not interchromosomal recombination in
yeast (Scheistl, 1993). The induction of inversions in response to all of
these agents suggested that chromosomal inversion was a common muta-
tional response to different DNA damaging agents with different mecha-
nisms of genotoxic action. 
THE PKZ1 IN VIVO ASSAY IS EXTREMELY SENSITIVE IN SPLEEN TISSUE
When lower doses of DNA damaging agents were studied, it was
found that the pKZ1 recombination mutagenesis assay was extremely sen-
sitive compared with other in vivo mutation assays. For cyclophos-
phamide, an induction of inversions was observed at doses that were 4
orders of magnitude lower (Sykes et al. 1998) than doses which had pre-
viously been shown to induce point mutations in the BigBlue® mutagen-
esis assay (Köhler et al. 1991). For etoposide, a change in inversion fre-
quency was observed at doses that were an order of magnitude lower than
had been studied in other assays. However, not only was the assay more
sensitive, the dose response followed a J-curve (Fig 4A) (Hooker et al.
2002) with low doses of etoposide causing a reduction below endogenous
inversion frequency suggesting that low doses of etoposide may be anti-
mutagenic. Etoposide is a known mutagen causing point mutations, small
and large deletions, insertions and illigitimate recombination in mam-
malian cells (Berger et al. 1991; Han et al. 1993; Maraschin et al. 1990; and
Ferguson and Baguley, 1996). There have been no reports in other muta-
Sensitive mutation assay for low dose studies
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tion assays showing a reduction below endogenous frequency in response
to low dose etoposide exposure. A significant reduction below endoge-
nous inversion frequency was also detected in pKZ1 spleen after 25 days
of 4 W/kg, 900 MHz radiofrequency exposure (Sykes et al. 2001).
Whether 900 Mhz radiofrequency can cause genotoxicity in other muta-
tion assays is controversial as is a possible mode of genotoxicity (reviewed
in Brusick et al. 1998). In the case of acute whole body X-radiation,
changes in inversion frequency were observed at doses that were at least
three orders of magnitude lower than other investigators had reported
for other mutation end-points, and in this case the dose response was
even more complex than a J-curve. We have termed this response an S-
curve response (Fig 5) (Hooker et al. 2004b). These results suggested that
ultra-low doses of X-radiation were more mutagenic than low doses and
that low doses may be anti-mutagenic. An induction of inversions was
observed in pKZ1 mice with single acute whole body X-radiation expo-
sures of ultra-low doses of 5 and 10 μGy. At these doses bystander effects
must be playing a role as the number of cells sustaining damage directly
P. J. Sykes, A. A. Morley, and A. M. Hooker
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FIGURE 4: Inversion frequency ± SE (ratio of treated/control) A) in vivo in pKZ1 spleen three days
after a single intraperitoneal injection with etoposide and B) in vitro in a pKZ1 cell line three days
after exposure to etoposide for 6 hours. n = 5, *statistically significant (p <0.05, two tailed T-test)
(Hooker et al. 2002).
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from the radiation must only constitute a small fraction of the cells pres-
ent (Azzam et al. 2003; Hall and Hei, 2003; Morgan, 2003; Mothersill and
Seymour, 2003). Bystander effects may also be playing a role in response
to very low doses of chemical DNA damaging agents. The results with low
doses of etoposide and X-radiation do not conform to a LNT dose
response model. Based on the same dose-response patterns that have
been emerging through our studies, it is possible that had we continued
to study lower doses of the other agents above, we might well have
observed a similar dose-response pattern to that shown in Fig 5.
PKZ1 IN VITRO ASSAY
In vivo mutation assays are time-consuming and expensive, and study-
ing mechanism in vivo can be difficult. We therefore developed a pKZ1
hybridoma cell line by fusing pKZ1 spleen cells with a myeloma cell line
and then selected clones which contained the pKZ1 transgene (Hooker
et al. 2002). One cell line (A11) which was chosen for subsequent study
has an endogenous inversion frequency of 1 × 10–3 which is approxi-
mately 10-fold higher than the endogenous inversion frequency in
spleen. The higher frequency may be the result of genomic instability in
a vigorously growing immortal cell line or of increased recombination
associated with rapid replication. The endogenous inversion frequency in
A11 was studied over a 4 month period in culture (31 passages) and was
Sensitive mutation assay for low dose studies
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FIGURE 5: Inversion frequency ± SE (ratio of treated/control) in pKZ1 spleen three days after X-
irradiation. Inversions were induced in pKZ1 spleen at ultra-low and at high doses of radiation expo-
sure. Intermediate (low) doses of radiation caused a decrease below endogenous inversion frequen-
cy. * Statistically significiant (p<0.05, two-tailed T-test) (Hooker et al. 2004b)
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demonstrated to be relatively stable, fluctuating around a mean of 1.13 ±
0.12 × 10–3 (Fig 6). The A11 line has been used to study low doses of
etoposide in vitro (Fig 4b) (Hooker et al. 2002). The pKZ1 A11 cell line
responded in the same dose dependent manner in response to etoposide
as was observed in vivo in that a J-curve response was observed. The low-
est etoposide dose studied was 10-fold lower than had previously been
reported to modulate a mutation end-point. There was no difference
observed in proliferation at the lower doses compared with vehicle con-
trol indicating that the reduction in inversion frequency below endoge-
nous inversion frequency was not largely proliferation dependent. The
demonstration that a J-curve dose response was observed for etoposide
both in vivo and in vitro confirmed that the pKZ1 assay is measuring a
mutagenic response that is fundamental to the cell regardless of whether
it is in immortalised cells in culture or cells present in spleen tissue in a
live animal (Fig 4). 
WHY ARE SIMILAR NON-LINEAR DOSE RESPONSE CURVES NOT
OBSERVED IN OTHER MUTATION ASSAYS? 
Non-linear dose response curves have been identified for a number
of different biological end-points (reviewed in Calabrese and Baldwin,
2001b) but there is limited data demonstrating non-linear dose-response
curves in mutation assays. 
By contrast with most mutation assays, the pKZ1 assay has a very high
endogenous inversion frequency in spleen tissue of approximately 1.5 ×
P. J. Sykes, A. A. Morley, and A. M. Hooker
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FIGURE 6: Endogenous inversion frequency in pKZ1 hybridoma A11 cells (mean ± SE). Endogenous
inversion frequency was analysed by histochemistry over a period of approximately 4 months for cells
in continuous culture. n = 5 for all groups except for passage 16 where n = 2.
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10–4 and 1 x 10–3 in the A11 cell line. This high frequency makes it feasi-
ble to observe a reduction below endogenous inversion frequency. Assays
which have endogenous mutation frequencies of 1 × 10–6 would require
enormous numbers of cells to be studied to observe significant reduc-
tions below the endogenous mutation frequency. This may be the reason
why the non-linear dose response is rarely observed in other mutation
assays. The results of the S-curve response for X-radiation suggest that
investigators may have the opportunity to identify subsequent increases in
mutation frequency with other mutation assays but may not have looked
at doses that are several orders of magnitude lower than the doses at
which no changes were observed previously in such assays. One µGy acute
radiation dose is the lowest dose studied in the pKZ1 mice to date. Future
experiments studying doses below 1 μGy still need to be performed to
determine whether 1 μGy is the threshold radiation dose below which no
changes in inversion frequency occur. Further low dose experiments also
need to be performed to determine the threshold dose for the other
chemical DNA damaging agents previously studied in pKZ1 animals.
WHY IS THE PKZ1 ASSAY SO SENSITIVE?
Effectively, the pKZ1 assay measures the ability of a cell to invert the
lacZ transgene. In order for this to occur the chromatin must be
unwound to enable a stem and loop structure to occur, and then that
structure needs to be recognised by proteins which resolve the stem and
loop structure into an inversion. The proteins involved are likely to be
those involved in non-homologous end-joining (NHEJ) recombination as
the molecular break-point identified in spleen tissue bears the heptamer-
nonamer signature sequence of immunoglobulin gene rearrangements
which occur via a NHEJ mechanism (Sykes et al. 1998; Hooker et al.
2004a). However, inversion events with this same signature sequence have
been identified in pKZ1 tissues that do not express the RAG1/RAG2 com-
plex known to be essential for immunoglobulin gene rearrangement
(Matsuoka et al. 1991; Hooker et al. 2004a). pKZ1 mice have been crossed
with RAG1 knock-out mice to make pKZ1/RAG1 knock-out mice. The
progeny still underwent inversions in lymphocytes but the inversions did
not involve the recombination signal sequences and only short regions of
homology were involved (H. Sakano and F. Nagawa, personal communi-
cation). These results indicate that more ubiquitous enzymes involved in
NHEJ-type processes may be involved. Regardless of the exact NHEJ
enzymes involved, we hypothesise that the inversions in the pKZ1 gene
act as a surrogate measure of NHEJ activity in a cell. Therefore an inver-
sion detected in the pKZ1 transgene will not necessarily be due to repair
of damage in the transgene DNA sequence. Instead, inversions can result
from NHEJ activity as a response to DNA damage that has occurred any-
where in the genomic DNA of that cell or even in neighbouring cells
Sensitive mutation assay for low dose studies
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where bystander effects are involved. This hypothesis would account for
the exquisite sensitivity of the pKZ1 assay. The actual damage to the DNA
incurred by direct interaction with a DNA damaging agent may be linear
but the repair response may not be. It is the responses of the cell (at least
at low doses) to the damage that will ultimately be important for the sub-
sequent mutational load and survival of the cell, rather than the direct
amount of DNA damage at these low doses. 
THE PKZ1 IN VIVO ASSAY CAN BE USED TO STUDY THE EFFECT OF
CANCER-ASSOCIATED GENES ON INVERSION FREQUENCY
Chromosomal inversions are common mutations in cancer and we
hypothesised that genes frequently altered in cancer would play a role in
formation of chromosomal inversions. It has been difficult to study the
effect of cancer-associated genes on chromosomal changes prior to
tumour formation in vivo because of a lack of appropriate test systems. We
utilised the pKZ1 assay to test this hypothesis by breeding pKZ1 mice to
three tumour model strains, Eµ-myc (Corcoran et al. 1985), Msh-2 knock-
out (de Wind et al. 1995) and transgenic adenocarcinoma mouse prostate
(TRAMP) (Greenberg et al. 1995), to produce double-transgenic animals
(Hooker et al. 2004a). The three tumour models studied involved over-
expression of the c-myc proto-oncogene (resulting in lymphoma), loss of
Msh-2 (resulting in lymphoma) and expression of the SV40 T antigen
(resulting in prostate tumours) respectively. The frequency of chromoso-
mal inversions was affected in the case of all three cancer associated genes
studied. An increase in inversions was demonstrated in spleen of animals
over-expressing c-myc and a decrease in inversions was observed in spleen
of animals lacking Msh-2 and in luminal epithelial or basal cells of pro-
static glands of animals expressing the SV40 T antigen. We hypothesise
that the increase and decrease in inversions in the presence of cancer
associated genes results from inappropriate NHEJ activity. These data sug-
gest that the pKZ1 model may provide a powerful tool for studying the
effect of cancer associated genes on chromosomal aberrations in the
early stages of carcinogenesis as well as being a useful model for studying
low dose effects. 
ADVANTAGES AND DISADVANTAGES OF THE PKZ1 ASSAYS FOR STUDY-
ING LOW DOSES OF DNA DAMAGING AGENTS
The pKZ1 assay has many advantages for the study of low doses of
DNA damaging agents, as it is very sensitive and the high endogenous
inversion frequency enables detection of decreases below endogenous
inversion frequency. The model also exhibits modulation of inversion fre-
quency over a very wide range of dose. The magnitude of the response to
any one dose is not large, but the dose response is still clearly identified
P. J. Sykes, A. A. Morley, and A. M. Hooker
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and may represent the limit of variation of NHEJ activity. The J-curve
response has been identified both in vivo and in vitro which suggests that
a fundamental mechanism is involved in modulation of inversion events
whether in an artificial biological situation in vitro or in the metabolic and
physiologically relevant biological system of a complete mammal. Direct
histochemical analysis of tissues can enable identification of the types of
cells which are undergoing inversions in response to DNA damaging
agents. This is a major advantage compared with in vivo mutagenesis
assays which require isolation of DNA from the tissues and subsequent
analysis in a second vector system, such as BigBlue® (Köhler et al. 1991),
Muta™Mouse (Myhr, 1991) and the deletion model of Gossen et al.
(1995). The COR3 mouse model by Murti et al. (1994) and the mouse
pink-eye model by Brilliant et al. (1991) enable the study of mutations at
the cellular level, but are restricted to the study of testis, or patches of eye
and coat colour respectively. The main disadvantage of the pKZ1 assays is
that screening tissue sections and cell lines for blue staining is labour
intensive and the endpoint is visual scoring. It takes considerable time for
staff to become competent at screening as the blue stain forms a small
defined dot in cells which have undergone inversions. These small dots
can be missed in the screening if the histochemical staining is subopti-
mal. False positives can also be scored if there is significant non-specific
background staining. In order to ensure that these are not confounding
problems in scoring, all tissues from any one experiments are always cut
and stained on the same day and all slides are screened blind, whereby
the slides are coded by another individual in the laboratory and the code
is not broken until all the slides in an experiment have been screened.
Both treated and untreated non-transgenic animal controls are also
always included to control for X-gal staining and any effects that treat-
ment may have on X-gal staining. Attempts are presently in progress to
develop a quantitative real-time polymerase chain reaction to detect the
inversion event in lymphoid tissue at the DNA level. Such an assay would
remove subjective bias and allow larger numbers of cells to be screened
rapidly. However, different tissues do exhibit different inversion break-
points (unpublished data) and therefore only a subset of inversions will
be scored at any one time in a real-time PCR. However, a number of dif-
ferent PCR’s to the different break-points could be designed and com-
pared quantitatively.
SUMMARY
The pKZ1 mutation assays fit the majority of the criteria set by
Calabrese and Baldwin (2001a) for low dose studies. The assays are sensi-
tive over a wide dose range and have the capacity to detect non-linear
dose responses due to their high endogenous frequencies. Our results to
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date using the pKZ1 in vivo and in vitro assays suggest that the LNT dose-
response model may not hold for all DNA damaging agents. Inversions in
pKZ1 spleen have been studied almost exclusively to date, but there is the
potential to study a wide range of pKZ1 tissues both at the cellular and
the molecular level. The pKZ1 in vivo assay has the potential to be used
to study the effect of cancer genes in the early stages of carcinogenesis
and may be useful for the study of low doses of DNA damaging agents in
the presence of aberrant cancer gene expression. 
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